Last reviewed 2026-04-20 · How we verify

Panzyga

Panzyga, marketed by Octapharma, is an immunoglobulin G (IgG) therapy primarily indicated for the treatment of immune thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP). The drug's key strength lies in its well-established safety and efficacy profile, supported by robust clinical trial results. The primary risk to Panzyga's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generic alternatives.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies (PHASE2)
• Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) (PHASE3)
• Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections (PHASE3)
• Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) (PHASE3)
• Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients (PHASE3)
• Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) (PHASE4)
• Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma (PHASE3)
• Non-Interventional Study on the Tolerability and Efficacy of IVIG

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.